Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase.
Carosati, E., Tochowicz, A., Marverti, G., Guaitoli, G., Benedetti, P., Ferrari, S., Stroud, R.M., Finer-Moore, J., Luciani, R., Farina, D., Cruciani, G., Costi, M.P.(2012) J Med Chem 55: 10272-10276
- PubMed: 23075414 
- DOI: https://doi.org/10.1021/jm300850v
- Primary Citation of Related Structures:  
4E28 - PubMed Abstract: 
Human thymidylate synthase (hTS) was targeted through a virtual screening approach. The most optimal inhibitor identified, 2-{4-hydroxy-2-[(2-hydroxybenzylidene)hydrazono]-2,5-dihydrothiazol-5-yl}-N-(3-trifluoromethylphenyl)acetamide (5), showed a mixed-type inhibition pattern, with a K(i) of 1.3 μM and activity against ovarian cancer cell lines with the same potency as cisplatin. X-ray studies revealed that it binds the inactive enzyme conformation. This study is the first example of a nonpeptidic inhibitor that binds the inactive hTS and exhibits anticancer activity against ovarian cancer cells.
Organizational Affiliation: 
Dipartimento di Chimica, Università degli Studi di Perugia , Via Elce di Sotto 10, 06123, Perugia, Italy.